XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.

European stocks slip ahead of US inflation data, GSK jumps



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-European stocks slip ahead of US inflation data, GSK jumps</title></head><body>

Tech stocks lead morning slide

U.S. inflation data at 1230 GMT

GSK to settle Zantac lawsuits, stock up

Updated at 0825 GMT

By Paolo Laudani and Sruthi Shankar

Oct 10 (Reuters) - European shares slipped on Thursday, with technology and mining stocks leading losses, while investors looked out U.S. inflation data for hints on the Federal Reserve's next policy easing moves.

The pan-European STOXX 600 index .STOXX was down 0.2%, with tech .SX8P, mining .SXPP and travel and leisure .SXTP stocks leading morning declines.

European stocks were under pressureas bondyields rose on Thursday, with the German 10-year yield hitting a fresh one-month high, tracking overnight gains in U.S. Treasury yields. US/

Wall Street indexes touched record highs on Wednesday after the Fed's September meeting minutes showed a "substantial majority" of officials supported an outsized half-point rate cut, without committing to a particular pace of cuts in the future.

Data at 1230 GMT (8:30 a.m. ET) is expected to show U.S. consumer prices rose 0.1% in September on a month-over-month basis, compared with a 0.2% increase in August. Traders are currently pricing in an 85% chance of a smaller 25-basis-point reductionfrom the Fed next month.

"Markets are muted as they're waiting to see what happens with the U.S.CPI (consumer price index) and, more importantly, what's happening on Saturday morning in China," said Stefan Koopman, senior market economist at Rabobank.

"If we get a cooler-than-expected CPI, it won't raise expectations of a 50-basis-point cut; I think the risk is not symmetrical on that report."

The STOXX 600 has been choppy this week as uncertainty around Beijing'sstimulus plans weighed on sentiment. China's finance ministry will detail plans on fiscal stimulus at a highly anticipated news conference on Saturday.

Investors will also focus on the French government's 2025 budget later on Thursday, with plans for 60 billion euros ($65.68 billion) worth of tax hikes and spending cuts to tackle a spiralling fiscal deficit.

Markets are likely to pay close attention to whether the budget can get through parliament without being watered down too much.

"It should be a very credible budget and if it's not, French assets will be at risk tomorrow morning," said Rabobank's Koopman.

Among individual stocks, GSK GSK.L jumped 5.2% after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the United States that claimed its discontinued heartburn drug Zantac caused cancer. The figure was smaller than what some analysts had feared.

Shares in Italy's fourth-largest bank BPER EMII.MI rose 7.6% to touch a nine-year high after the lender provided a new 2024-2027 business plan.



Reporting by Paolo Laudani in Gdansk and Sruthi Shankar in Bengaluru; Editing by Eileen Soreng and Sonia Cheema

</body></html>

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.